Drugs / GLPG2451
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03540524 | May 2018 → Mar 2019 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03214614 | Nov 2016 → Aug 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02788721 | Apr 2016 → Apr 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-06-20 | Lakefront Biotherapeutics NV | Results Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗
Galapagos reports that Phase 1 results on GLPG2451, GLPG2222 and GLPG2737 showed favorable findings relating to safety and tolerability of the individual components that constitute our current most advanced potential triple combination therapy. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-06-20 | Lakefront Biotherapeutics NV | Galapagos’ R&D Update 2017: rapidly advancing our product candidates lakefrontbio.com ↗ |
| 2017-02-23 | Lakefront Biotherapeutics NV | Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 lakefrontbio.com ↗ |
| 2016-05-09 | Lakefront Biotherapeutics NV | Galapagos starts Phase 1 study with potentiator GLPG2451 for CF lakefrontbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG2451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02788721 ↗ |
| Route | Oral | “GLPG2451 oral suspension, single ascending doses, daily” NCT02788721 ↗ |